greeksoup/ stocks
Stocks / United States / RMD / Q1 FY2026

Resmed Inc. Q1 FY2026 results: revenue $1.3 billion, up 9.1% on the year

Resmed Inc. (RMD) reported revenue of $1.3 billion for Q1 FY2026, the quarter ended 30 September 2025, up 9.1% on the same quarter a year earlier. Net income was $349 million, up 11.9% on the year, and diluted earnings per share $2.37. The figures are the company's own, from the 10-Q it filed with the SEC on 31 October 2025.

Revenue$1.3 billionup 9.1%
Net income$349 millionup 11.9%
Diluted EPS$2.37
QuarterQ1 FY2026ended 30 September 2025

The quarter, against the one before and a year earlier

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Revenue1,3361,3481,225+9.1%
Cost of revenue515528507+1.5%
Gross profit821820717+14.4%
Gross margin61.5%60.8%58.6%
Research and development87.386.479.5+9.8%
Selling, general and administrative259265239+8.5%
Operating income447455387+15.3%
Operating margin33.4%33.7%31.6%
Pre-tax income447458383+16.5%
Income tax98.378.372.1+36.2%
Effective tax rate22.0%17.1%18.8%
Net income349380311+11.9%
Net margin26.1%28.2%25.4%
Diluted EPS$2.37$2.58$2.11+12.3%

$ million except per share. Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Operating cash flow457539326+40.5%
Capital expenditure43.030.617.8+140.8%
Free cash flow414508308+34.7%
Free cash flow margin31.0%37.7%25.1%
Depreciation and amortisation47.763.644.7+6.6%
Share-based compensation21.224.820.2+5.0%
Buybacks15010050.0+200.0%
Dividends paid87.877.677.9+12.7%
Dividend per share$0.60n/a$0.53+13.2%
Diluted shares, weighted147m147m148m-0.5%
Shares outstanding at period end146m146m147m-0.6%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Total assets8,3088,1747,222+15.0%
Cash and equivalents1,3841,209426+224.6%
Receivables907939811+11.8%
Inventory946928918+3.0%
Goodwill3,0443,0472,886+5.5%
Total debt, as filed669668677-1.3%
Long-term debt409658668-38.8%
Borrowings, as the company tags them410660670-38.8%
Operating lease liabilities148153144+2.3%
Shareholders' equity6,1215,9685,195+17.8%

Quarterly results, the last 12 quarters

Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026 *
Revenue1,1021,1631,1971,2231,2251,2821,2921,3481,3361,4231,4311,464
Cost of revenue502516504508507531525528515544540602
Gross profit600647693716717751766820821879891861
Gross margin54%56%58%58%59%59%59%61%61%62%62%59%
R&D75.773.977.180.979.581.483.986.487.391.094.3106
SG&A223222230242239242245265259278286296
Operating income289275375381387417426455447492500449
Operating margin26%24%31%31%32%33%33%34%33%35%35%31%
Pre-tax income272259375358383418418458447496502474
Tax rate19%20%20%18%19%18%13%17%22%21%21%19%
Net income219209300292311345365380349393399383
Net margin20%18%25%24%25%27%28%28%26%28%28%26%
Diluted EPS$1.49$1.42$2.04$1.97$2.11$2.34$2.48$2.58$2.37$2.68$2.74$2.64
Operating cash flow286273402440326309579539457340554455
Capital expenditure30.023.421.224.917.820.620.830.643.028.533.751.1
Free cash flow256249381415308288558508414311520404
Buybacks0.050.050.050.050.075.075.0100150175175200
Dividends paid70.670.770.570.677.977.777.777.687.887.687.287.1
Shares outstanding147m147m147m147m147m147m147m146m146m146m145m144m
Filing10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 30 September 2025, filed 31 October 2025, accession 0000943819-25-000090: the filing on EDGAR. All of Resmed Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install